SCMP Share Price

Open 12.55 Change Price %
High 12.60 1 Day -0.45 -3.57
Low 11.90 1 Week 0.40 3.40
Close 12.15 1 Month 0.95 8.48
Volume 342222 1 Year -1.02 -7.74
52 Week High 17.55
52 Week Low 9.59
SCMP Important Levels
Resistance 2 12.80
Resistance 1 12.53
Pivot 12.22
Support 1 11.77
Support 2 11.50
NASDAQ USA Most Active Stocks
CTRP 47.59 1.13%
ADBE 119.47 -0.13%
FSLR 33.57 -8.33%
FSLR 33.57 -8.33%
CERN 55.37 0.18%
BIDU 186.01 0.21%
AAPL 137.11 0.30%
AAPL 137.11 0.30%
FB 136.12 1.79%
MASI 87.05 2.03%
More..
NASDAQ USA Top Gainers Stocks
VALV 0.05 66.67%
LOCM 0.09 50.00%
BASI 1.33 31.68%
WRES 0.09 28.57%
INAP 2.31 27.62%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
AETI 2.40 23.08%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
LIWA 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP)

SCMP Technical Analysis 3
As on 22nd Feb 2017 SCMP Share Price closed @ 12.15 and we RECOMMEND Sell for LONG-TERM with Stoploss of 12.18 & Sell for SHORT-TERM with Stoploss of 13.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
SCMP Target for February
1st Target up-side 13.13
2nd Target up-side 14.52
3rd Target up-side 15.91
1st Target down-side 9.17
2nd Target down-side 7.78
3rd Target down-side 6.39
SCMP Other Details
Segment EQ
Market Capital 208269664.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.sucampo.com
SCMP Address
SCMP
4520 East-West Highway
3rd Floor
Bethesda, MD 20814
United States
Phone: 301-961-3400
Fax: 301-961-3440
SCMP Latest News
Interactive Technical Analysis Chart Sucampo Pharmaceuticals, Inc. ( SCMP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sucampo Pharmaceuticals, Inc.
SCMP Business Profile
Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company focused on research, discovery, development and commercialization of drugs based on ion channel activators known as prostones. The Company�s prostone-based compounds target the ClC-2 and big potassium (BK), ion channels. It is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other therapeutic applications of its drug technology. The Company�s products include AMITIZA (lubiprostone) and RESCULA (unoprostone isopropyl). AMITIZA is marketed in the United States for three gastrointestinal indications: chronic idiopathic constipation (CIC), in adults, irritable bowel syndrome with constipation (IBS-C), in adult women, and opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. RESCULA is a BK channel activator and has a different mechanism of action than other IOP lowering agents on the market.